恒瑞医药(600276.SH)药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received a drug registration application acceptance notice from the National Medical Products Administration for its innovative drug, injection Karilizumab combined with Apalutamide capsules for first-line treatment of recurrent or metastatic cervical cancer patients [1] Group 1: Drug Approval and Indications - The injection Karilizumab has been approved for multiple indications in China, including treatment for advanced hepatocellular carcinoma patients who have previously received Sorafenib and/or systemic chemotherapy with Oxaliplatin since March 2020 [1] - Apalutamide capsules were approved in May 2025 for use in combination with injection Karilizumab for recurrent or metastatic cervical cancer patients who have failed platinum-based chemotherapy but have not received Bevacizumab treatment [1]